Anti-Microcephaly Vaccine-Blocker Candidate: Based on Zika Virus Gene Replikins in Human Fetal Microcephaly

Wednesday, August 3, 2016 Tropical Disease News
Email Print This Page Comment bookmark
Font : A-A+

TORONTO, Aug. 2, 2016 /PRNewswire/ -- Following the report earlier this month that significant mutations have been detected

in Zika gene structures*, Replikins, Ltd. Canada announced today that particular Replikins structures have been found in the Zika virus genes of microcephaly cases.

Logo - http://photos.prnewswire.com/prnh/20160802/395058LOGO

Photo

- http://photos.prnewswire.com/prnh/20160802/395059

These form the basis of the design of Synthetic Replikins Microcephaly Vaccine-Blocker candidates (Attached figure: all individual Zika specimens in Pubmed January, 2016, with Ebola for comparison).

Microcephaly of fetuses is the most dreaded outcome of the current Zika outbreaks. Replikins vaccine-blocker candidates appear to be the first to target the specific chemistry of the Zika virus gene related to microcephaly.

Replikins vaccines are produced in as little as seven days by solid phase synthesis, freeze-dried, permitting delivery without refrigeration (Google: "Replikins Reuters").

Contact:  Samuel Bogoch  Email  646-320-5910  www.replikins.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anti-microcephaly-vaccineblocker-candidate-based-on-zika-virus-gene-replikins-in-human-fetal-microcephaly-300307869.html

SOURCE Replikins Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store